Loading…
Consider strategies to address gut dysbiosis and explore antibacterial peptides to potentially lower the risk of small intestinal bacterial overgrowth (SIBO).
Our read is that lowering the risk of SIBO may involve addressing gut dysbiosis, particularly overgrowths of gram-negative bacteria. These bacteria are high in lipopolysaccharides and are associated with both SIBO and SIFO. Additionally, an antibacterial peptide has shown promise in combating SIBO.
Our sources did not raise any specific risks or disagreements regarding these approaches.
The verdict would change if additional expert claims provided more detailed methods for lowering SIBO risk, presented conflicting evidence, or introduced new supporting or refuting facts.
Mechanistic and trial evidence converge on a real, replicable effect.
Benefits hold across the populations where it's been tested.
The intervention improves the primary outcome at standard doses in healthy adults.
The intervention improves the primary outcome at standard doses in healthy adults.
Mechanistic and trial evidence converge on a real, replicable effect.
Confounding and publication bias inflate the apparent benefit.
Animal-model results don't translate to the human protocol being recommended.
Animal-model results don't translate to the human protocol being recommended.
Most of the support comes from short or small studies.
The headline effect shrinks once you account for trial quality.